Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Cidara Therapeutics Inc
CDTXCurrent price
26.49 USD
+1.5 USD (+6.00%)
Last closed
21.04 USD
Company
www.cidara.com
ISIN
US1717572069
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
272 884 608 USD
Yield for 12 month
+135.26 %
1Y
3Y
5Y
10Y
15Y
CDTX
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California. Address: 6310 Nancy Ridge Drive, San Diego, CA, United States, 92121
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
36.60 USDP/E ratio
–Dividend Yield
–Current Year
+1 275 000 USD
Last Year
+63 905 000 USD
Current Quarter
–
Last Quarter
–
Current Year
+1 042 000 USD
Last Year
+62 382 000 USD
Current Quarter
–
Last Quarter
–
Key Figures CDTX
1 year
3 years
5 years
10 years
EBITDA
-107 792 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-55.20 %
PEG Ratio
–
Return On Equity TTM
-299.58 %
Wall Street Target Price
36.60 USD
Revenue TTM
302 000 USD
Book Value
11.61 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-100.00 %
Dividend Yield
–
Gross Profit TTM
-71 800 000 USD
Earnings per share
-26.68 USD
Diluted Eps TTM
-26.68 USD
Most Recent Quarter
I 2025
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics CDTX
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History CDTX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:20
Payout Ratio TTM
–
Last Split Date
24.04.2024
Stock Valuation CDTX
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
5.75
Enterprise Value Revenue
358.45
Price Sales TTM
903.59
Enterprise Value EBITDA
-1.64
Price Book MRQ
1.93
Financials CDTX
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators CDTX
For 52 weeks
10.14 USD
28.42 USD
50 Day MA
20.60 USD
Shares Short Prior Month
480 028
200 Day MA
17.63 USD
Short Ratio
2.80
Shares Short
452 539
Short Percent
3.61 %
BeatStart